Global Ulcerative Colitis Market: Simponi and Entyvio Launches to Boost Growth by 2022
NEW YORK, LONDON, BERLIN, PARIS, February 19, 2014 /PRNewswire/ --
Reportstack has announced a newly published market intelligence report on Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 . The global ulcerative colitis (UC) market value will increase steadily over the coming years, growing from almost $4.2 billion in 2012 to approximately $6.6 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 4.7%. The company's latest report states that out of the 10 major countries (the US, Canada, France, Germany, Italy, Spain, the UK, Japan, China and India), the US will continue to hold the largest UC market share by 2020, with 52%. France and Germany will follow with shares of 11% and 8%, respectively.
Johnson & Johnson (J&J) has been continually dominating the UC market due to the success of Remicade. However, Remicade's patent is set to expire between 2015 and 2018, which will knock J&J's sales down from approximately $2 billion in 2012 to $1.5 billion by 2022, according to GlobalData. Another key player in the UC industry, AbbVie's Humira, will also lose its patent during the forecast period, with sales slipping from $1.2 billion in 2012 to $569 million by 2022.
However, the UC market will receive a major boost with the entry of J&J's Simponi and Takeda's Entyvio, with sales expected to reach an estimated $576 million and $1.3 billion by 2022, respectively. A senior Analyst covering Immunology, says: "Simponi shows better efficacy in UC than Humira and will therefore allow J&J to retain its positive standing in the UC industry for a longer period of time. On the other hand, Entyvio will have a slow start before gradually reaching blockbuster status, as a result of its remarkably safe profile for a biologic drug."
Still, a number of barriers will limit any further growth in the UC market, including the lack of curative therapy, diagnostic markers for disease severity, and biologic treatment personalization.
The analyst concludes: "There is also a major need for preventive medicine that lowers the associated risk of colorectal cancer, as well as demand for steroid replacement, oral formulations and the management of infectious adverse events."
During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. The companies that are mentioned in this report are J&J, AbbVie, Takeda, Warner Chilcott, Salix/Santarus, Shire, Ferring, Pfizer and InDeX Pharmaceuticals.
To view the detailed table of contents or to order this report kindly visit - Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
Related Reports from Reportstack:
Reportstack is one of the leading distributors of market research reports in the world today. Reportstack.com provides access to over 50,000 company profiles and their strategic information like SWOT analysis, deals and partnerships analysis, merger & acquisition activity and new product launches. Reportstack is also a leader in the field of Pharma market research & Medical Devices Market Research Reports.
SOURCE M/S. Reportstack